stockrow
Friday 6 November 2026
Export VAXX’s income statement to Excel — free account
Vaxxinity, Inc.
VAXX Healthcare Biotechnology
0.00
0.01
−100.00%
Follow VAXX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Trend | 10 yrs | 2024e | 2025e | 2026e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 0 | — | — | (88.2%) | 7 | 15 | — | +129.9% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 90.66 | (2,834.85) | 0.00 | — | 0.0 pt | ||||||
| EBT | — | — | — | — | — | (14) | (40) | (137) | (75) | (57) | +41.6% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | (7,173.61) | (207,840.91) | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | 0 | — | (14) | (40) | (137) | (75) | (57) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | (0.42) | (0.61) | (1.79) | (0.60) | (0.45) | +2.0% | ||||||
| Cash flow | — | — | — | — | — | (0.36) | (0.52) | (1.06) | (0.44) | (0.45) | +6.0% | ||||||
| Capex | — | — | — | — | — | 0.00 | (0.02) | (0.02) | (0.01) | (0.01) | n/m | ||||||
| Free cash flow | — | — | — | — | — | (0.36) | (0.54) | (1.07) | (0.46) | (0.46) | +6.4% | ||||||
| Book value | — | — | — | — | — | (1.42) | (1.33) | 1.68 | 0.49 | 0.11 | n/m | ||||||
| Shares, m | — | — | — | — | — | 34 | 66 | 77 | 126 | 127 | +38.7% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | — | 0.0 | |||||
| P/S | — | — | — | — | — | — | 1,822.86 | 2,347.83 | — | — | 2,085.3 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 3.34 | — | — | 1.7 | ||||||
| EV/Sales | — | — | — | — | — | — | 1,696.24 | 1,611.58 | — | — | 1,653.9 | ||||||
| EV/FCF | — | — | — | — | — | — | (13.26) | (3.56) | — | — | (8.4) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (12) | (34) | (81) | (56) | (57) | +47.0% | |||||
| Capex | — | — | — | — | — | — | (1) | (1) | (2) | (1) | (18.4%) | ||||||
| Free cash flow | — | — | — | — | — | (12) | (35) | (82) | (58) | (58) | +47.5% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (18) | (4) | 127 | 63 | 16 | n/m | |||||
| Net debt | — | — | — | — | — | 1 | (20) | (135) | (75) | (17) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | (49) | (87) | 129 | 62 | 13 | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (1,782.95) | (154.46) | (126.54) | (55.09) | (75.55) | +1,707.4 pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 20.93 | 58.81 | (665.19) | (78.85) | (150.65) | (171.6) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | 75 | 89 | 89 | 65 | (4.7%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2021 · latest quarter Dec 2021 · fundamentals updated 25 Oct 2026
Vaxxinity, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $15.6M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $15.6M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.5M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | |
| ABOS Acumen Pharmaceuticals, Inc. | $15.5M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.3M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| PLUR Pluri Inc. | $15.0M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| Median of peers | $15.4M | — | — | −51.00% | — | +18.81% | 62.79% | 0.00% |